Approval of medical marijuana has been on a significant uptick in various states of the US, trailed by the legalization in Canada for both recreational and medicinal use recently. This has tremendously contributed to the popularity of cannabis stocks, alongside efforts of leading controlled substance manufacturers toward eliminating legal barriers and attracting investor interest. The study estimates marijuana sales in 2019 to record a Y-o-Y growth at 9.3% over 2018.
Request for the Report Summary: https://www.factmr.com/report/2032/controlled-substances-market
“The Schedule of Controlled Substances currently positions marijuana in Schedule 1 – the most restrictive one reserved for “high potential for abuse,” “lack of accepted safety” and “no accepted medical use” drugs. Federal scheduling of marijuana has been a key concern among producers and medical patients alike, despite legalization of cannabis in the US and Canada. The US Drug Enforcement Administration has recently removed cannabidiol from Schedule 1, post-FDA approval of non-synthetic, cannabis-derived medicine. Marijuana businesses have cheered the DEA’s action, as it alludes the beginning of regulatory relaxation to the cannabis industry,” according to a lead analyst at Fact.MR.
The study opines that pain management will continue to account for over one-fourth share of the controlled substances market in 2018. Several regulatory norms being implemented in the prescription of controlled substances for pain management, such as in Georgia, Michigan, and Florida, have further triggered the preference and adoption of controlled substances to manage and treat chronic as well as acute pain. Attention deficit hyperactivity disorder (ADHD), and anxiety are other medical conditions wherein controlled substances are expected to witness promising future prospects, according to the study.
Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=2032
The entrance of pharmaceutical giants in the cannabis sector of Canada alludes the next significant trend in the controlled substances industry, offering additional credibility to the sector. Although the pharmaceutical part of the expression involves the missing link, an ongoing trend of M&A and entrance of these legacy industries is poised in 2019 and the foreseeable future. There has been a drought in direct investments from the pharmaceutical industries in the licensed medical marijuana producers, it is highly likely that the trend would change, as the US witnesses the federal legalization of cannabis. Big pharmaceutical companies that eye collaborations and partnerships with cannabis producers having competitive differentiation circling their R&D initiatives, commercialization efforts, and clinical trial programs, are likely to witness significant revenue generation in the near future.
Ensuring effective and safe management of controlled drugs continues to remain an imperative agenda among pharmacists, which in turn has led the focus on fundamental changes including reviewing of liquid CD management and CD documentation to realize substantial improvements. The pharmacists are also adhering to the operational standards, completely aware about the way CDs are managed, along with identifying potential drawbacks and reporting concerns regarding non-conformance. This will result in adherence to appropriate steps that ensure apt prescription of quantities when dispensing controlled substances to patients.
Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=2032
About Us
Fact.MR’s methodology is robust and comprehensive. We employ a range of tools and assets to develop an all-encompassing coverage of a range of industries. We compile data points at local, country, regional, and global level – our approach to capturing the finest nuances, without losing sight of the bigger picture helps us in developing accurate and reliable forecasts and estimates.
Fact.MR has a standard set of guidelines and standards that help maintain a level of consistency across all of our research offerings. The standardization includes step-by-step documentation of the methodologies and guidelines on the sources that are to be used for incorporation of objective and accurate data.
The standardization also involves use of industry-wide analytical tools, and rigorous quality checks to validate market forecasts and sizes. Our unwavering focus on standardization ensures that clients receive the same quality of research and analysis that Fact.MR is known for.
Contact Us
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
E: [email protected]
Blog: https://theheraldmedia.com/
Worldwide sales of the controlled substances closed in on a valuation of US$ 67,000 Mn in 2018, and are projected to record a Y-o-Y growth at 3.5% in 2019, according to a new Fact.MR study.
The study opines that depressants and stimulants have been top-selling class of drugs in the controlled substances market, however gains from marijuana are expected to record over 2X faster growth than all the other controlled substances in 2019 and beyond.The controlled substances market report highlights the following players:Teva Pharmaceuticals, Inc.Johnson & JohnsonDaiichi Sankyo CompanyTakeda Pharmaceutical Company LimitedOthersThe controlled substances market report examines the operating pattern of each player – new product launches, partnerships, and acquisitions – has been examined in detail.Approval of medical marijuana has been on a significant uptick in various states of the US, trailed by the legalization in Canada for both recreational and medicinal use recently.
This has tremendously contributed to the popularity of cannabis stocks, alongside efforts of leading controlled substance manufacturers toward eliminating legal barriers and attracting investor interest.
The study estimates marijuana sales in 2019 to record a Y-o-Y growth at 9.3% over 2018.Pain Management Remains Leading Application of Controlled SubstancesThe study opines that pain management will continue to account for over one-fourth share of the controlled substances market in 2018.
Several regulatory norms being implemented in the prescription of controlled substances for pain management, such as in Georgia, Michigan, and Florida, have further triggered the preference and adoption of controlled substances to manage and treat chronic as well as acute pain.
Attention deficit hyperactivity disorder (ADHD), and anxiety are other medical conditions wherein controlled substances are expected to witness promising future prospects, according to the study.Request For a Sample Report - https://www.factmr.com/connectus/sample?flag=S_id=2032The entrance of pharmaceutical giants in the cannabis sector of Canada alludes the next significant trend in the controlled substances industry, offering additional credibility to the sector.
Looking into the global marketspace for controlled substances, Fact.MR has concluded some vital observations which highlights the burgeoning demand for such products.
According to this recently published study titled “Controlled Substances Market Forecast, Trend Analysis & Competition Tracking – Global Market Insights 2018 to 2028”, it has been revealed that growing preference for medical marijuana over prescription drugs to control headaches, back problems, depression and pain, despite criminalization, indicates current public health structure that believes cannabis moderation becoming outdated.
This assessment carefully unravels essential data associated to prime market specifics including market outlook, demand side trends, pipeline assessment, Y-o-Y growth trend analysis, forecast factors as well as market dynamics that comprise of drivers, opportunity and restraints.Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S_id=2032Popularity of Medical Marijuana Uplifting Investor Interest towards Controlled Substances It has been noticed that approval of medical marijuana has turned out to be a significant boost in various states of the US.
Such events have greatly contributed to the popularity of cannabis shares, together with efforts of leading controlled substance companies toward abolishing legal barriers as well as attracting investor interest.
For example, in Georgia, Florida and Michigan, the triggered preference as well as adoption of controlled substances for treating chronic and acute pain have enhanced.
In addition, attention deficit hyperactivity disorder (ADHD), as well as anxiety are some other medical conditions which are managed using controlled substance.
Are you looking for a fully licensed Fingerprint Recovery Laboratory in Newark, then this is a good opportunity for you to contact Nikoui & Associates.
Here you will find forensic services expert and experienced in the analysis of controlled substances, based on which you can find a You can reach the facts as soon as possible by visiting the website now and get more information
Tramadol is a synthetic opioid medication used for the treatment of moderate to moderate severe pain. It may also be prescribed for pain resulting from an injury or post surgical pain and such medical conditions as cancer. It is frequently prescribed when over-the-counter pain drugs did not prove effective in bringing relief from pain. In order the get fast relief from the symptoms of pain without going outside, buy tramadol online.
Are you a medical marijuana enthusiast? If so, you would know how challenging it can be to find a home which allows the use medical marijuana. Not every landlord or property owner allows its use in the premises of the building. Smoking cannabis in a building where it’s prohibited can foster your landlord to evict you if you are caught smoking. But what can you do if you are asked to leave?
Learn more about it here at http://bit.ly/2DoEW0K.
The global E-prescribing market size is projected to reach USD 4,017.79 million by 2026 owing to the implementation of e-prescribing software in the electronic health record solutions that simplified prescription filling over the years.
E-prescribing or electronic prescribing is a technology substructure that allows physicians and medical practitioners to send computer-based electronically generated prescriptions to a hospital-based or standalone pharmacy.For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/e-prescribing-market-102698It is also cost-efficient and reduces the chances of medication errors by pharmacists.
The market is discussed in details in a recently published report by Fortune Business Insights™ titled, “E-prescribing Market Size, Share & Industry Analysis, By Delivery Mode (Web-based, On-premise), By Prescription Type (Controlled substance, Non controlled Substances) By End User (Hospitals, Physician's offices, Pharmacies) and Regional Forecast, 2019-2026.” As per this report, the market value was USD 863.64 million in 2018 and is expected to rise at a CAGR of 21.0 % in the forecast duration set between 2019 to 2026.What are the Report Highlights?The report is based on an in-depth analysis of the market and provides a 360-degree overview of the same.
It throws light on significant industry developments, current e-prescribing market trends, and other interesting insights into the market.
It discusses factors boosting, repelling, challenging, ad creating opportunities for the market during the forecast period.
The report also describes the table of segmentation in detail and mentions the names and figures of the leading segments with their attributed factors.
